Advertisement

Topics

EMD Serono Company Profile

04:04 EDT 17th October 2017 | BioPortfolio

EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, is a leader in the US biopharmaceutical arena, integrating cutting-edge science with unparalleled patient support systems to improve people's lives. The company has strong market positions in neurodegenerative diseases, with Rebif® (interferon beta-1a), as well as in endocrinology, with Saizen® (somatropin (rDNA origin) for injection), Serostim® (somatropin (rDNA origin) for injection) and EGRIFTATM (tesamorelin for injection). EMD Serono is a leader in reproductive health, with Gonal-f® (follitropin alfa for injection), Luveris® (lutropin alfa for injection) and Ovidrel® Prefilled Syringe (choriogonadotropin alfa injection). In addition, EMD Serono is growing its expertise and presence in the area of oncology, with more than 10 projects currently in development. With a clear focus on the patient and a leadership presence in the biopharmaceutical industry, EMD Serono’s US footprint continues to grow, with more than 1100 employees around the country and fully integrated commercial, clinical and research operations in the company’s home state of Massachusetts.


News Articles [26 Associated News Articles listed on BioPortfolio]

Merck Serono: Launching a New Corporate Venture Fund

In this episode of PharmaTelevision News Review, Paul Larsmon talks with Roel Bulthuis, Head at Merck Serono Ventures. Filmed at BIO-Europe 2009, they discuss: • Merck Serono's new corporate venture...

Roel Bulthuis of Merck Serono Ventures- looking for new investment opportunities in oncology, neurodegeneration, inflammation, fertility and endocrinology

In this episode of PharmaTelevision News Review, Fintan Walton talks to Roel Bulthuis, Head of Merck Serono Ventures of Merck Serono SA

Merck Serono Secures Future Pipeline

In March 2009 Merck Serono announced that they had set up a strategic Venture Fund to invest in biotech companies with interesting programmes that are in line with Merck Serono’s strategic thinking....

FDA designates orphan status to EMD Serono's gastric cancer drug

Merck KGaA unit EMD Serono's Bavencio, or avelumab, was given orphan drug designation by the FDA to treat patients with gastr -More- 

Phillippe Lopes-Fernandes talks about Merck Serono’s strengths and successes in partnering

In this episode of PharmaTelevision News Review, Fintan Walton talks to Phillippe Lopes-Fernandes, Corporate VP, Head of Global Business Development at Merck Serono

EMD Serono: Philippe M Lopes-Fernandes. Closure of Geneva site creates opportunities for new business successes

In this episode of PharmaTelevision News Review, filmed at BioEurope Spring 2013, in Barcelona, Spain, Fintan Walton talks to Philippe M Lopes-Fernandes, Senior VP, Head of Global Licensing, Business ...

EMD Serono Release: Investigational Cladribine Tablets Demonstrates Sustained Disease Control Over 4 Years With Maximum Of 20 Days Oral Treatment

  Life Sciences Jobs   ...

Vaccine Problems, PTV News: Mar 24, 2010

Merck Serono suspends trials of Stimuvax cancer vaccine after encephalitis case

Drugs and Medications [6 Associated Drugs and Medications listed on BioPortfolio]

Saizen [EMD Serono, Inc.]

Saizen [somatropin (rDNA origin) for injection] For subcutaneous or intramuscular injection

Zorbtive [EMD Serono, Inc.]

Zorbtive [somatropin (rDNA origin) for injection]

Serophene [EMD Serono, Inc.]

Serophene (clomiPHENE citrate tablets USP)

Rebif [EMD Serono, Inc.]

Rebif (interferon beta-1a)

Gonal-f rff pen [EMD Serono, Inc.]

Gonal-f® RFF Pen (follitropin alfa injection) *revised formulation female For subcutaneous injection

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

Avelumab: First Global Approval.

Avelumab (Bavencio(®)) is an intravenously administered programmed cell death ligand-1-blocking human antibody initially developed by EMD Serono Inc. (the biopharmaceutical division of Merck KGaA, Da...

Clinical Trials [14 Associated Clinical Trials listed on BioPortfolio]

Efficacy and Tolerability of Human FSH Versus Recombinant FSH (Follitropin Alpha) in ICSI.

Purpose of the study is the comparative evaluation of the clinical efficacy and of the general tolerability of two different subcutaneous FSH preparations (Fostimon® IBSA Vs Gonal-F® Ser...

Study of EMD531444 in Subjects With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy

Darmstadt, Germany, June 17 2010 - Merck Serono, a division of Merck KGaA, and its U.S. affiliate, EMD Serono, Inc. today announced that they are resuming their Stimuvax® (BLP25 liposome ...

Long Protocol and Freeze All Embryos vs Antagonist Protocol With Fresh Embryo Transfer in PCOS Patients Undergoing ICSI

Patients will be divided into two groups Group A; patients using long protocol and freeze all embryos Group B; patients using antagonist protocol with fresh embryo transfer Patients will b...

Clinical Tolerance and Equivalence of hCG-IBSA vs Recombinant Human Chorionic Gonadotrophin in Women Undergoing In Vitro Fertilisation

The purpose of the study is to evaluate the clinical equivalence and the general tolerability of two different subcutaneous hCG preparations (hCG-IBSA, IBSA vs Ovitrelle, Serono) when admi...

Subcutaneous Progesterone Supplementation in Patients With Endometriosis

The aim of the study protocol will be to compare the efficacy of subcutaneous progesterone (25 mg / day; Pleyris, IBSA Institut Biochimique SA) with vaginal progesterone (90 mg / day; Crin...

Companies [32 Associated Companies listed on BioPortfolio]

Merck Serono

Merck Serono is the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, a global pharmaceutical and chemical company. Headquartered in Geneva, Switzerland, Merck Serono ...

Serono Inc.

Serono is a global biotechnology leader with over 4,750 employees and worldwide revenues of USD 2,586.4 million in the year 2005. We have eight biotechnology products on the market and currently more ...

Serono Laboratories Incorporated

We develop innovative products to fight debilitating diseases and improve the lives of our patients.We aspire to create an environment that enables our people to excel and innovate and to contribute t...

Serono France SA

Nil

Serono Symposia International Foundation

More Information about "EMD Serono" on BioPortfolio

We have published hundreds of EMD Serono news stories on BioPortfolio along with dozens of EMD Serono Clinical Trials and PubMed Articles about EMD Serono for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of EMD Serono Companies in our database. You can also find out about relevant EMD Serono Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...


Corporate Database Quicklinks



Searches Linking to this Company Record